DETERMINANTS OF A2 ADRENORECEPTOR-N-PROTEIN INTERACTIONS

Information

  • Research Project
  • 3353307
  • ApplicationId
    3353307
  • Core Project Number
    R01HL037551
  • Full Project Number
    5R01HL037551-03
  • Serial Number
    37551
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/1/1987 - 37 years ago
  • Project End Date
    1/31/1991 - 33 years ago
  • Program Officer Name
  • Budget Start Date
    2/1/1989 - 35 years ago
  • Budget End Date
    1/31/1991 - 33 years ago
  • Fiscal Year
    1989
  • Support Year
    3
  • Suffix
  • Award Notice Date
    1/1/2999 - 975 years from now

DETERMINANTS OF A2 ADRENORECEPTOR-N-PROTEIN INTERACTIONS

The Alpha2 adrenergic receptor (AR) inhibits the ubiquitous regulatory enzyme adenylate cyclase via an interaction with a guanine nucleotide binding protein, Ni. This or similar quanine nucleotide binding proteins (N-proteins) may also have other functions such as regulation of phospholipase C or membrane potassium channels. The interaction of the Alpha2 AR with N-proteins has not been well characterized. The experiments will study the factors that control coupling of the Alpha2 AR with N-proteins by use of three approaches. First, selective inactivation of receptors with high and low affinity for agonists will be done to identify receptor heterogeneity that controls the interaction with N-proteins. The effect of such selective modification on inhibition of adenylate cyclase and stimulation of GTPase will also be studied. Second, reconstitution of Alpha2 AR and N-proteins will permit variation in both the identity (Ni vs No) and concentration of the components. Agonist binding will be compared to theoretical predictions for a ternary complex model of receptor N-protein interactions and differences between Alpha2 AR coupling with Ni and No will be evaluated. Finally, studies of solubilized Alpha2 AR using reconstitution, affinity labeling and purification will characterize the structural substrate of Alpha2 AR heterogeneity. A better understanding of Alpha2 AR mechanisms may yield new approaches to the study of pathophysiology and treatment of disorders such as hypertension, Alzheimer's disease and depression.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
  • Funding Mechanism
  • Study Section
    PHRA
  • Study Section Name
    Pharmacology A Study Section
  • Organization Name
    UNIVERSITY OF MICHIGAN AT ANN ARBOR
  • Organization Department
  • Organization DUNS
    791277940
  • Organization City
    ANN ARBOR
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    481091274
  • Organization District
    UNITED STATES